HF 2508

CCR--HF2508 - 87th Legislature (2011 - 2012)

Posted on 04/19/2012 10:23 a.m.

1.1CONFERENCE COMMITTEE REPORT ON H. F. No. 2508 1.2A bill for an act 1.3relating to public safety; aligning state-controlled substance schedules with 1.4federal controlled substance schedules; modifying the authority of the Board of 1.5Pharmacy to regulate controlled substances; providing for penalties;amending 1.6Minnesota Statutes 2010, section 152.02, as amended; Minnesota Statutes 2011 1.7Supplement, section 152.027, subdivision 6. 1.8April 17, 2012 1.9The Honorable Kurt Zellers 1.10Speaker of the House of Representatives 1.11The Honorable Michelle L. Fischbach 1.12President of the Senate 1.13We, the undersigned conferees for H. F. No. 2508 report that we have agreed upon 1.14the items in dispute and recommend as follows: 1.15That the Senate recede from its amendments and that H. F. No. 2508 be further 1.16amended as follows: 1.17Delete everything after the enacting clause and insert: 1.18    "Section 1. Minnesota Statutes 2010, section 152.02, as amended by Laws 2011, 1.19chapter 53, sections 4 and 5, is amended to read: 1.20152.02 SCHEDULES OF CONTROLLED SUBSTANCES; 1.21ADMINISTRATION OF CHAPTER. 1.22    Subdivision 1. Five schedules. There are established five schedules of controlled 1.23substances, to be known as Schedules I, II, III, IV, and V. Such new text begin The new text end schedules shall 1.24initially consist of the substances listed in this section by whatever official name, common 1.25or usual name, chemical name, or trade name designated. 1.26    Subd. 2. Schedule I. The following items are listed in Schedule I: new text begin (a) Schedule I new text end 1.27 new text begin consists of the substances listed in this subdivision. new text end 1.28(1) new text begin (b) Opiates. Unless specifically excepted or unless listed in another schedule, new text end 1.29any of the following substances, including their new text begin analogs, new text end isomers, esters, ethers, salts, and 1.30salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence 2.1of the new text begin analogs, new text end isomers, esters, ethers and salts is possible within the specific chemical 2.2designation: 2.3 new text begin (1) new text end acetylmethadol; 2.4 new text begin (2) new text end allylprodine; 2.5 new text begin (3) new text end alphacetylmethadol new text begin (except levo-alphacetylmethadol, also known as new text end 2.6 new text begin levomethadyl acetate) new text end ; 2.7 new text begin (4) new text end alphameprodine; 2.8 new text begin (5) new text end alphamethadol; 2.9 new text begin (6) alpha-methylfentanyl new text end benzethidine; 2.10 new text begin (7) new text end betacetylmethadol; 2.11 new text begin (8) new text end betameprodine; 2.12 new text begin (9) new text end betamethadol; 2.13 new text begin (10) new text end betaprodine; 2.14 new text begin (11) new text end clonitazene; 2.15 new text begin (12) new text end dextromoramide; dextrorphan; 2.16 new text begin (13) new text end diampromide; 2.17 new text begin (14) new text end diethyliambutene; 2.18 new text begin (15) difenoxin; new text end 2.19 new text begin (16) new text end dimenoxadol; 2.20 new text begin (17) new text end dimepheptanol; 2.21 new text begin (18) new text end dimethyliambutene; 2.22 new text begin (19) new text end dioxaphetyl butyrate; 2.23 new text begin (20) new text end dipipanone; 2.24 new text begin (21) new text end ethylmethylthiambutene; 2.25 new text begin (22) new text end etonitazene; 2.26 new text begin (23) new text end etoxeridine; 2.27 new text begin (24) new text end furethidine; 2.28 new text begin (25) new text end hydroxypethidine; 2.29 new text begin (26) new text end ketobemidone; 2.30 new text begin (27) new text end levomoramide; 2.31 new text begin (28) new text end levophenacylmorphan; 2.32 new text begin (29) 3-methylfentanyl; new text end 2.33 new text begin (30) acetyl-alpha-methylfentanyl; new text end 2.34 new text begin (31) alpha-methylthiofentanyl; new text end 2.35 new text begin (32) benzylfentanyl beta-hydroxyfentanyl; new text end 2.36 new text begin (33) beta-hydroxy-3-methylfentanyl; new text end 3.1 new text begin (34) 3-methylthiofentanyl; new text end 3.2 new text begin (35) thenylfentanyl; new text end 3.3 new text begin (36) thiofentanyl; new text end 3.4 new text begin (37) para-fluorofentanyl; new text end 3.5 new text begin (38) new text end morpheridine; 3.6 new text begin (39) 1-methyl-4-phenyl-4-propionoxypiperidine; new text end 3.7 new text begin (40) new text end noracymethadol; 3.8 new text begin (41) new text end norlevorphanol; 3.9 new text begin (42) new text end normethadone; 3.10 new text begin (43) new text end norpipanone; 3.11 new text begin (44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP); new text end 3.12 new text begin (45) new text end phenadoxone; 3.13 new text begin (46) new text end phenampromide; 3.14 new text begin (47) new text end phenomorphan; 3.15 new text begin (48) new text end phenoperidine; 3.16 new text begin (49) new text end piritramide; 3.17 new text begin (50) new text end proheptazine; 3.18 new text begin (51) new text end properidine; 3.19 new text begin (52) propiram; new text end 3.20 new text begin (53) new text end racemoramide; 3.21 new text begin (54) tilidine; new text end 3.22 new text begin (55) new text end trimeperidine. 3.23(2) new text begin (c) Opium derivatives. new text end Any of the following opium derivatives new text begin substances new text end , 3.24their new text begin analogs, new text end salts, isomers new text begin , new text end and salts of isomers, unless specifically excepted new text begin or unless new text end 3.25 new text begin listed in another schedule new text end , whenever the existence of the new text begin analogs, new text end salts, isomers and salts 3.26of isomers is possible within the specific chemical designation: 3.27 new text begin (1) new text end acetorphine; 3.28 new text begin (2) new text end acetyldihydrocodeine; acetylcodone; 3.29 new text begin (3) new text end benzylmorphine; 3.30 new text begin (4) new text end codeine methylbromide; 3.31 new text begin (5) new text end codeine-n-oxide; 3.32 new text begin (6) new text end cyprenorphine; 3.33 new text begin (7) new text end desomorphine; 3.34 new text begin (8) new text end dihydromorphine; 3.35 new text begin (9) new text end new text begin drotebanol; new text end 3.36 new text begin (10) new text end etorphine; 4.1 new text begin (11) new text end heroin; 4.2 new text begin (12) new text end hydromorphinol; 4.3 new text begin (13) new text end methyldesorphine; methylhydromorphine 4.4 new text begin (14) methyldihydromorphine new text end ; 4.5 new text begin (15) new text end morphine methylbromide; 4.6 new text begin (16) new text end morphine methylsulfonate; 4.7 new text begin (17) new text end morphine-n-oxide; 4.8 new text begin (18) new text end myrophine; 4.9 new text begin (19) new text end nicocodeine; 4.10 new text begin (20) new text end nicomorphine; 4.11 new text begin (21) new text end normorphine; 4.12 new text begin (22) new text end pholcodine; 4.13 new text begin (23) new text end thebacon. 4.14(3) new text begin (d) new text end new text begin Hallucinogens. new text end Any material, compound, mixture or preparation which 4.15contains any quantity of the following hallucinogenic substances, their new text begin analogs, new text end salts, 4.16isomers (whether optical, positional, or geometric), and salts of isomers, unless specifically 4.17excepted or unless listed in another schedule, whenever the existence of the new text begin analogs, new text end salts, 4.18isomers, and salts of isomers is possible: 4.193,4-methylenedioxy amphetamine new text begin (1) methylenedioxy amphetamine new text end ; 4.203,4-methylenedioxymethamphetamine new text begin (2) methylenedioxymethamphetamine new text end ; 4.21 new text begin (3) methylenedioxy-N-ethylamphetamine (MDEA); new text end 4.22 new text begin (4) n-hydroxy-methylenedioxyamphetamine; new text end 4.23 new text begin (5) new text end 4-bromo-2,5-dimethoxyamphetamine new text begin (DOB) new text end ; 4.24 new text begin (6) new text end 2,5-dimethoxyamphetamine new text begin (2,5-DMA) new text end ; 4.25 new text begin (7) new text end 4-methoxyamphetamine; 4.26 new text begin (8) new text end 5-methoxy-3, 4-methylenedioxy amphetamine; 4.27 new text begin (9) alpha-ethyltryptamine; new text end 4.28 new text begin (10) new text end bufotenine; 4.29 new text begin (11) new text end diethyltryptamine; 4.30 new text begin (12) new text end dimethyltryptamine; 4.31 new text begin (13) new text end 3,4,5-trimethoxy amphetamine; 4.32 new text begin (14) new text end 4-methyl-2, 5-dimethoxyamphetamine new text begin (DOM) new text end ; 4.33 new text begin (15) new text end ibogaine; 4.34 new text begin (16) new text end lysergic acid diethylamide new text begin (LSD) new text end ; marijuana; 4.35 new text begin (17) new text end mescaline; 4.36 new text begin (18) parahexyl; new text end 5.1 new text begin (19) new text end N-ethyl-3-piperidyl benzilate; 5.2 new text begin (20) new text end N-methyl-3-piperidyl benzilate; 5.3 new text begin (21) new text end psilocybin; 5.4 new text begin (22) new text end psilocyn; 5.5Tetrahydrocannabinols; 1-(1-(2-thienyl) cyclohexyl) piperidine new text begin (23) tenocyclidine new text end 5.6 new text begin (TPCP or TCP) new text end ; 5.7 new text begin (24) new text end N-ethyl-1-phenyl-cyclohexylamine new text begin (PCE) new text end ; 5.8 new text begin (25) new text end 1-(1-phenylcyclohexyl) pyrrolidine new text begin (PCPy); new text end 5.9 new text begin (26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy); new text end 5.10 new text begin (27) 4-chloro-2,5-dimethoxyamphetamine (DOC); new text end 5.11 new text begin (28) 4-ethyl-2,5-dimethoxyamphetamine (DOET); new text end 5.12 new text begin (29) 4-iodo-2,5-dimethoxyamphetamine (DOI); new text end 5.13 new text begin (30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B); new text end 5.14 new text begin (31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C); new text end 5.15 new text begin (32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD) new text end ; 5.162,5-dimethoxy-4-ethylphenethylamine, also known as new text begin (33) new text end 5.17 new text begin 4-ethyl-2,5-dimethoxyphenethylamine ( new text end 2C-E new text begin ) new text end ; 5.182,5-dimethoxy-4-iodophenethylamine, also known as new text begin (34) new text end 5.19 new text begin 4-iodo-2,5-dimethoxyphenethylamine ( new text end 2C-I new text begin ); new text end 5.20 new text begin (35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P); new text end 5.21 new text begin (36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4); new text end 5.22 new text begin (37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7); new text end 5.23 new text begin (38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine new text end 5.24 new text begin (2-CB-FLY); new text end 5.25 new text begin (39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY); new text end 5.26 new text begin (40) alpha-methyltryptamine (AMT); new text end 5.27 new text begin (41) N,N-diisopropyltryptamine (DiPT); new text end 5.28 new text begin (42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT); new text end 5.29 new text begin (43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET); new text end 5.30 new text begin (44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT); new text end 5.31 new text begin (45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT); new text end 5.32 new text begin (46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT); new text end 5.33 new text begin (47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); new text end 5.34 new text begin (48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT); new text end 5.35 new text begin (49) 5-methoxy-α-methyltryptamine (5-MeO-AMT); new text end 5.36 new text begin (50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT); new text end 6.1 new text begin (51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT); new text end 6.2 new text begin (52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT); new text end 6.3 new text begin (53) 5-methoxy-α-ethyltryptamine (5-MeO-AET); new text end 6.4 new text begin (54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT); new text end 6.5 new text begin (55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET); new text end 6.6 new text begin (56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT); new text end 6.7 new text begin (57) methoxetamine (MXE); new text end 6.8 new text begin (58) 5-iodo-2-aminoindane (5-IAI); new text end 6.9 new text begin (59) 5,6-methylenedioxy-2-aminoindane (MDAI) new text end . 6.10(4) new text begin (e) new text end Peyote, providing new text begin . new text end new text begin All parts of the plant presently classified botanically as new text end 6.11 new text begin Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract new text end 6.12 new text begin from any part of the plant, and every compound, manufacture, salts, derivative, mixture, new text end 6.13 new text begin or preparation of the plant, its seeds or extracts. new text end The listing of peyote as a controlled 6.14substance in Schedule I does not apply to the nondrug use of peyote in bona fide religious 6.15ceremonies of the American Indian Church, and members of the American Indian Church 6.16are exempt from registration. Any person who manufactures peyote for or distributes 6.17peyote to the American Indian Church, however, is required to obtain federal registration 6.18annually and to comply with all other requirements of law. 6.19(5) new text begin (f) Central nervous system depressants. new text end Unless specifically excepted or unless 6.20listed in another schedule, any material compound, mixture, or preparation which contains 6.21any quantity of the following substances having a depressant effect on the central nervous 6.22system, including its new text begin , their analogs, new text end salts, isomers, and salts of isomers whenever the 6.23existence of the new text begin analogs, new text end salts, isomers, and salts of isomers is possible within the specific 6.24chemical designation: 6.25 new text begin (1) new text end mecloqualone; 6.26 new text begin (2) methaqualone; new text end 6.27 new text begin (3) gamma-hydroxybutyric acid (GHB), including its esters and ethers; new text end 6.28 new text begin (4) new text end flunitrazepam. 6.29(6) new text begin (g) Stimulants. new text end Unless specifically excepted or unless listed in another schedule, 6.30any material compound, mixture, or preparation which contains any quantity of the 6.31following substances having a stimulant effect on the central nervous system, including its new text begin , new text end 6.32 new text begin their analogs, new text end salts, isomers, and salts of isomers whenever the existence of the new text begin analogs, new text end 6.33salts, isomers, and salts of isomers is possible within the specific chemical designation: 6.34     new text begin (1) aminorex; new text end 6.35 new text begin (2) new text end cathinone; 6.36 new text begin (3) fenethylline; new text end 7.1     new text begin (4) new text end methcathinone; 7.2 new text begin (5) methylaminorex; new text end 7.3 new text begin (6) N,N-dimethylamphetamine; new text end 7.4 new text begin (7) N-benzylpiperazine (BZP); new text end 7.54-methylmethcathinone new text begin (8) methylmethcathinone new text end (mephedrone); 7.6 new text begin (9) new text end 3,4-methylenedioxy-N-methylcathinone (methylone); 7.74-methoxymethcathinone new text begin (10) methoxymethcathinone new text end (methedrone); 7.83,4 - methylenedioxypyrovalerone new text begin (11) methylenedioxypyrovalerone new text end (MDPV) new text begin ; new text end 7.9 new text begin (12) fluoromethcathinone; new text end 7.10 new text begin (13) methylethcathinone (MEC); new text end 7.11 new text begin (14) 1-benzofuran-6-ylpropan-2-amine (6-APB); new text end 7.12 new text begin (15) dimethylmethcathinone (DMMC); new text end 7.13 new text begin (16) fluoroamphetamine; new text end 7.14 new text begin (17) fluoromethamphetamine; new text end 7.15 new text begin (18) α-methylaminobutyrophenone (MABP or buphedrone); new text end 7.16 new text begin (19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone); new text end 7.17 new text begin (20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378); new text end 7.18 new text begin (21) naphthylpyrovalerone (naphyrone); new text end 7.19 new text begin (22) and any other substance, except bupropion or compounds listed under a new text end 7.20 new text begin different schedule, that is structurally derived from 2-aminopropan-1-one by substitution new text end 7.21 new text begin at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not new text end 7.22 new text begin the compound is further modified in any of the following ways: new text end 7.23 new text begin (i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, new text end 7.24 new text begin haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring new text end 7.25 new text begin system by one or more other univalent substituents; new text end 7.26 new text begin (ii) by substitution at the 3-position with an acyclic alkyl substituent; new text end 7.27 new text begin (iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or new text end 7.28 new text begin methoxybenzyl groups; or new text end 7.29 new text begin (iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure new text end . 7.30(7) new text begin (h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. new text end Unless 7.31specifically excepted or unless listed in another schedule, any natural or synthetic material, 7.32compound, mixture, or preparation that contains any quantity of a substance that is a 7.33cannabinoid receptor agonist, including, but not limited to, the following substances and new text begin , new text end 7.34their analogs, including isomers, whether optical, positional, or geometric; esters; new text begin , new text end ethers; new text begin , new text end 7.35salts; new text begin , new text end and salts of isomers, esters, and ethers, whenever the existence of the isomers, 7.36esters, ethers, or salts is possible within the specific chemical designation: 8.11-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), 8.2(2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH-015), 8.31-Pentyl-3-(1-naphthoyl)indole (JWH-018), 1-hexyl-3-(naphthalen-1-oyl)indole 8.4(JWH-019), 1-Butyl-3-(1-naphthoyl)indole (JWH-073), 8.54-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-081), 8.64-methoxynaphthalen-1-yl-(1-pentyl-2-methylindol-3-yl)methanone 8.7(JWH-098), (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethanone 8.8(JWH-200), 7-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone 8.9(JWH-164), 2-(2-chlorophenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-203), 8.104-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone (JWH-210), 8.112-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250), 8.121-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), (6aR,10aR)- 8.139-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- 8.14tetrahydrobenzo[c]chromen-1-ol (HU-210), (R)-(+)-[2,3-Dihydro-5-methyl-3- 8.15(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone 8.16(WIN-55,212-2), 2-[3-hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol (CP47,497), 8.17dimethylheptylpyran. 8.18 new text begin (1) marijuana; new text end 8.19 new text begin (2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis, new text end 8.20 new text begin synthetic equivalents of the substances contained in the cannabis plant or in the new text end 8.21 new text begin resinous extractives of the plant, or synthetic substances with similar chemical structure new text end 8.22 new text begin and pharmacological activity to those substances contained in the plant or resinous new text end 8.23 new text begin extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans new text end 8.24 new text begin tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol; new text end 8.25 new text begin (3) synthetic cannabinoids, including the following substances: new text end 8.26 new text begin (i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole new text end 8.27 new text begin structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, new text end 8.28 new text begin alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or new text end 8.29 new text begin 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any new text end 8.30 new text begin extent and whether or not substituted in the naphthyl ring to any extent. Examples of new text end 8.31 new text begin naphthoylindoles include, but are not limited to: new text end 8.32 new text begin (A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678); new text end 8.33 new text begin (B) 1-Butul-3-(1-naphthoyl)indole (JWH-073); new text end 8.34 new text begin (C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081); new text end 8.35 new text begin (D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); new text end 8.36 new text begin (E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015); new text end 9.1 new text begin (F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019); new text end 9.2 new text begin (G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122); new text end 9.3 new text begin (H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210); new text end 9.4 new text begin (I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398); new text end 9.5 new text begin (J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201). new text end 9.6 new text begin (ii) Napthylmethylindoles, which are any compounds containing a new text end 9.7 new text begin 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom new text end 9.8 new text begin of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, new text end 9.9 new text begin 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further new text end 9.10 new text begin substituted in the indole ring to any extent and whether or not substituted in the naphthyl new text end 9.11 new text begin ring to any extent. Examples of naphthylmethylindoles include, but are not limited to: new text end 9.12 new text begin (A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175); new text end 9.13 new text begin (B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184). new text end 9.14 new text begin (iii) Naphthoylpyrroles, which are any compounds containing a new text end 9.15 new text begin 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the new text end 9.16 new text begin pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, new text end 9.17 new text begin 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not new text end 9.18 new text begin further substituted in the pyrrole ring to any extent, whether or not substituted in the new text end 9.19 new text begin naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to, new text end 9.20 new text begin (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307). new text end 9.21 new text begin (iv) Naphthylmethylindenes, which are any compounds containing a new text end 9.22 new text begin naphthylideneindene structure with substitution at the 3-position of the indene new text end 9.23 new text begin ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, new text end 9.24 new text begin 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further new text end 9.25 new text begin substituted in the indene ring to any extent, whether or not substituted in the naphthyl new text end 9.26 new text begin ring to any extent. Examples of naphthylemethylindenes include, but are not limited to, new text end 9.27 new text begin E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176). new text end 9.28 new text begin (v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole new text end 9.29 new text begin structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, new text end 9.30 new text begin alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or new text end 9.31 new text begin 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to new text end 9.32 new text begin any extent, whether or not substituted in the phenyl ring to any extent. Examples of new text end 9.33 new text begin phenylacetylindoles include, but are not limited to: new text end 9.34 new text begin (A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8); new text end 9.35 new text begin (B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250); new text end 9.36 new text begin (C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251); new text end 10.1 new text begin (D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203). new text end 10.2 new text begin (vi) Cyclohexylphenols, which are compounds containing a new text end 10.3 new text begin 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position new text end 10.4 new text begin of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, new text end 10.5 new text begin 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not new text end 10.6 new text begin substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include, new text end 10.7 new text begin but are not limited to: new text end 10.8 new text begin (A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497); new text end 10.9 new text begin (B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol new text end 10.10 new text begin (Cannabicyclohexanol or CP 47,497 C8 homologue); new text end 10.11 new text begin (C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl] new text end 10.12 new text begin -phenol (CP 55,940). new text end 10.13 new text begin (vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole new text end 10.14 new text begin structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, new text end 10.15 new text begin alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or new text end 10.16 new text begin 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to new text end 10.17 new text begin any extent and whether or not substituted in the phenyl ring to any extent. Examples of new text end 10.18 new text begin benzoylindoles include, but are not limited to: new text end 10.19 new text begin (A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4); new text end 10.20 new text begin (B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694); new text end 10.21 new text begin (C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone new text end 10.22 new text begin (WIN 48,098 or Pravadoline). new text end 10.23 new text begin (viii) Others specifically named: new text end 10.24 new text begin (A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) new text end 10.25 new text begin -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210); new text end 10.26 new text begin (B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) new text end 10.27 new text begin -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211); new text end 10.28 new text begin (C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de] new text end 10.29 new text begin -1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2). new text end 10.30(8) new text begin (i) new text end A controlled substance analog, to the extent that it is implicitly or explicitly 10.31intended for human consumption. 10.32    Subd. 3. Schedule II. The following items are listed in new text begin (a) new text end Schedule II: new text begin consists of new text end 10.33 new text begin the substances listed in this subdivision. new text end 10.34(1) new text begin (b) new text end Unless specifically excepted or unless listed in another schedule, any of 10.35the following substances whether produced directly or indirectly by extraction from 11.1substances of vegetable origin or independently by means of chemical synthesis, or by a 11.2combination of extraction and chemical synthesis: 11.3(a) new text begin (1) new text end Opium and opiate, and any salt, compound, derivative, or preparation 11.4of opium or opiate, including the following: raw opium, opium extracts, opium 11.5fluid extracts, powdered opium, granulated opium, tincture of opium, apomorphine, 11.6codeine, ethylmorphine, hydrocodone, hydromorphone, metopon, morphine, oxycodone, 11.7oxymorphone, thebaine. 11.8 new text begin (i) Excluding: new text end 11.9 new text begin (A) apomorphine; new text end 11.10 new text begin (B) thebaine-derived butorphanol; new text end 11.11 new text begin (C) dextrophan; new text end 11.12 new text begin (D) nalbuphine; new text end 11.13 new text begin (E) nalmefene; new text end 11.14 new text begin (F) naloxone; new text end 11.15 new text begin (G) naltrexone; new text end 11.16 new text begin (H) and their respective salts; new text end 11.17 new text begin (ii) but including the following: new text end 11.18 new text begin (A) opium, in all forms and extracts; new text end 11.19 new text begin (B) codeine; new text end 11.20 new text begin (C) dihydroetorphine; new text end 11.21 new text begin (D) ethylmorphine; new text end 11.22 new text begin (E) etorphine hydrochloride; new text end 11.23 new text begin (F) hydrocodone; new text end 11.24 new text begin (G) hydromorphone; new text end 11.25 new text begin (H) metopon; new text end 11.26 new text begin (I) morphine; new text end 11.27 new text begin (J) oxycodone; new text end 11.28 new text begin (K) oxymorphone; new text end 11.29 new text begin (L) thebaine; new text end 11.30 new text begin (M) oripavine; new text end 11.31(b) new text begin (2) new text end any salt, compound, derivative, or preparation thereof which is chemically 11.32equivalent or identical with any of the substances referred to in clause (a) new text begin (1) new text end , except that 11.33these substances shall not include the isoquinoline alkaloids of opium. new text begin ; new text end 11.34(c) new text begin (3) new text end opium poppy and poppy straw. new text begin ; new text end 11.35(d) new text begin (4) new text end coca leaves and any salt, new text begin cocaine new text end compound, derivative, or preparation 11.36of coca leaves, including cocaine and ecgonine, the salts and isomers of cocaine and 12.1ecgonine, and the salts of their isomers. new text begin (including cocaine and ecgonine and their salts, new text end 12.2 new text begin isomers, derivatives, and salts of isomers and derivatives), and any salt, compound, new text end 12.3 new text begin derivative, or preparation thereof which is chemically equivalent or identical with any of new text end 12.4 new text begin these substances, except that the substances shall not include decocainized coca leaves or new text end 12.5 new text begin extraction of coca leaves, which extractions do not contain cocaine or ecgonine; new text end 12.6(e) Any salt, compound, derivative, or preparation thereof which is chemically 12.7equivalent or identical with any of the substances referred to in clause (d), except that 12.8the substances shall not include decocainized coca leaves or extraction of coca leaves, 12.9which extractions do not contain cocaine or ecgonine. new text begin (5) concentrate of poppy straw (the new text end 12.10 new text begin crude extract of poppy straw in either liquid, solid, or powder form which contains the new text end 12.11 new text begin phenanthrene alkaloids of the opium poppy). new text end 12.12(2) new text begin (c) new text end Any of the following opiates, including their isomers, esters, ethers, salts, and 12.13salts of isomers, esters and ethers, unless specifically excepted, or unless listed in another 12.14schedule, whenever the existence of such isomers, esters, ethers and salts is possible 12.15within the specific chemical designation: 12.16 new text begin (1) new text end alfentanil; 12.17 new text begin (2) new text end alphaprodine; 12.18 new text begin (3) new text end anileridine; 12.19 new text begin (4) new text end bezitramide; 12.20 new text begin (5) bulk dextropropoxyphene (nondosage forms); new text end 12.21 new text begin (6) carfentanil; new text end 12.22 new text begin (7) new text end dihydrocodeine; 12.23 new text begin (8) new text end dihydromorphinone; 12.24 new text begin (9) new text end diphenoxylate; 12.25 new text begin (10) new text end fentanyl; 12.26 new text begin (11) new text end isomethadone; 12.27 new text begin (12) levo-alpha-acetylmethadol (LAAM) new text end levomethorphan; 12.28 new text begin (13) new text end levorphanol; 12.29 new text begin (14) new text end metazocine; 12.30 new text begin (15) new text end methadone; 12.31 new text begin (16) new text end methadone - intermediate, 4-cyano-2-dimethylamino-4, 4-diphenylbutane; 12.32 new text begin (17) new text end moramide - intermediate, 2-methyl-3-morpholino-1, 12.331-diphenyl-propane-carboxylic acid; 12.34 new text begin (18) new text end pethidine; 12.35 new text begin (19) new text end pethidine - intermediate - a, 4-cyano-1-methyl-4-phenylpiperidine; 12.36 new text begin (20) new text end pethidine - intermediate - b, ethyl-4-phenylpiperidine-4-carboxylate; 13.1 new text begin (21) new text end pethidine - intermediate - c, 1-methyl-4-phenylpiperidine-4-carboxylic acid; 13.2 new text begin (22) new text end phenazocine; 13.3 new text begin (23) new text end piminodine; 13.4 new text begin (24) new text end racemethorphan; 13.5 new text begin (25) new text end racemorphan new text begin ; new text end 13.6 new text begin (26) remifentanil; new text end 13.7 new text begin (27) sufentanil; new text end 13.8 new text begin (28) tapentadol new text end . 13.9(3) new text begin (d) new text end Unless specifically excepted or unless listed in another schedule, any 13.10material, compound, mixture, or preparation which contains any quantity of the following 13.11substances having a stimulant effect on the central nervous system: 13.12(a) new text begin (1) new text end amphetamine, its salts, optical isomers, and salts of its optical isomers; 13.13(b) new text begin (2) new text end methamphetamine, its salts, isomers, and salts of its isomers; 13.14(c) new text begin (3) new text end phenmetrazine and its salts; 13.15(d) new text begin (4) new text end methylphenidate new text begin ; new text end 13.16 new text begin (5) lisdexamfetamine new text end . 13.17(4) new text begin (e) new text end Unless specifically excepted or unless listed in another schedule, any 13.18material, compound, mixture, or preparation which contains any quantity of the following 13.19substances having a depressant effect on the central nervous system, including its salts, 13.20isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of 13.21isomers is possible within the specific chemical designation: 13.22(a) methaqualone 13.23(b) new text begin (1) new text end amobarbital new text begin ; new text end 13.24 new text begin (2) glutethimide; new text end 13.25(c) new text begin (3) new text end secobarbital new text begin ; new text end 13.26(d) new text begin (4) new text end pentobarbital new text begin ; new text end 13.27(e) new text begin (5) new text end phencyclidine new text begin ; new text end 13.28(f) new text begin (6) new text end phencyclidine immediate precursors: 13.29(i) 1-phenylcyclohexylamine new text begin ; new text end 13.30(ii) 1-piperidinocyclohexanecarbonitrile new text begin ; new text end 13.31 new text begin (7) phenylacetone new text end . 13.32 new text begin (f) Hallucinogenic substances: nabilone. new text end 13.33    Subd. 4. Schedule III. The following items are listed in new text begin (a) new text end Schedule III: new text begin consists of new text end 13.34 new text begin the substances listed in this subdivision. new text end 13.35(1) Any material, compound, mixture, or preparation which contains any quantity of 13.36Amphetamine, its salts, optical isomers, and salts of its optical isomers; Phenmetrazine 14.1and its salts; Methamphetamine, its salts, isomers, and salts of isomers; Methylphenidate; 14.2and which is required by federal law to be labeled with the symbol prescribed by 21 Code 14.3of Federal Regulations Section 1302.03 and in effect on February 1, 1976 designating that 14.4the drug is listed as a Schedule III controlled substance under federal law. new text begin (b) Stimulants. new text end 14.5 new text begin Unless specifically excepted or unless listed in another schedule, any material, compound, new text end 14.6 new text begin mixture, or preparation which contains any quantity of the following substances having new text end 14.7 new text begin a potential for abuse associated with a stimulant effect on the central nervous system, new text end 14.8 new text begin including its salts, isomers, and salts of such isomers whenever the existence of such salts, new text end 14.9 new text begin isomers, and salts of isomers is possible within the specific chemical designation: new text end 14.10 new text begin (1) benzphetamine; new text end 14.11 new text begin (2) chlorphentermine; new text end 14.12 new text begin (3) clortermine; new text end 14.13 new text begin (4) phendimetrazine. new text end 14.14(2) new text begin (c) Depressants. Unless specifically excepted or unless listed in another schedule, new text end 14.15any material, compound, mixture, or preparation which contains any quantity of the 14.16following substances having a potential for abuse associated with a depressant effect on 14.17the central nervous system: 14.18(a) new text begin (1) new text end any compound, mixture, or preparation containing amobarbital, secobarbital, 14.19pentobarbital or any salt thereof and one or more other active medicinal ingredients which 14.20are not listed in any schedule. new text begin ; new text end 14.21(b) new text begin (2) new text end any suppository dosage form containing amobarbital, secobarbital, 14.22pentobarbital, or any salt of any of these drugs and approved by the food and drug 14.23administration for marketing only as a suppository. new text begin ; new text end 14.24(c) new text begin (3) new text end any substance which contains any quantity of a derivative of barbituric acid, 14.25or any salt of a derivative of barbituric acid, except those substances which are specifically 14.26listed in other schedules: Chlorhexadol; Glutethimide; Lysergic acid; Lysergic acid amide; 14.27Methyprylon; Sulfondiethylmethane; Sulfonethylmethane; Sulfonmethane. new text begin ; new text end 14.28(d) Gamma hydroxybutyrate, any salt, compound, derivative, or preparation of 14.29gamma hydroxybutyrate, including any isomers, esters, and ethers and salts of isomers, 14.30esters, and ethers of gamma hydroxybutyrate whenever the existence of such isomers, 14.31esters, and salts is possible within the specific chemical designation. new text begin (4) any drug product new text end 14.32 new text begin containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, new text end 14.33 new text begin for which an application is approved under section 505 of the federal Food, Drug, and new text end 14.34 new text begin Cosmetic Act; new text end 14.35 new text begin (5) any of the following substances: new text end 14.36 new text begin (i) chlorhexadol; new text end 15.1 new text begin (ii) ketamine, its salts, isomers and salts of isomers; new text end 15.2 new text begin (iii) lysergic acid; new text end 15.3 new text begin (iv) lysergic acid amide; new text end 15.4 new text begin (v) methyprylon; new text end 15.5 new text begin (vi) sulfondiethylmethane; new text end 15.6 new text begin (vii) sulfonenthylmethane; new text end 15.7 new text begin (viii) sulfonmethane; new text end 15.8 new text begin (ix) tiletamine and zolazepam and any salt thereof; new text end 15.9 new text begin (x) embutramide. new text end 15.10(3) Any material, compound, mixture, or preparation which contains any quantity of 15.11the following substances having a potential for abuse associated with a stimulant effect on 15.12the central nervous system: 15.13(a) Benzphetamine 15.14(b) Chlorphentermine 15.15(c) Clortermine 15.16(d) Mazindol 15.17(e) Phendimetrazine. 15.18(4) new text begin (d) new text end Nalorphine. 15.19(5) Any material, compound, mixture, or preparation containing limited quantities 15.20of any of the following narcotic drugs, or any salts thereof new text begin (e) Narcotic drugs. Unless new text end 15.21 new text begin specifically excepted or unless listed in another schedule, any material, compound, new text end 15.22 new text begin mixture, or preparation containing any of the following narcotic drugs, or their salts new text end 15.23 new text begin calculated as the free anhydrous base or alkaloid, in limited quantities as follows new text end : 15.24(a) new text begin (1) new text end not more than 1.80 grams of codeine per 100 milliliters or not more than 90 15.25milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid 15.26of opium. new text begin ; new text end 15.27(b) new text begin (2) new text end not more than 1.80 grams of codeine per 100 milliliters or not more than 90 15.28milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized 15.29therapeutic amounts. new text begin ; new text end 15.30(c) new text begin (3) new text end not more than 300 milligrams of dihydrocodeinone per 100 milliliters or 15.31not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an 15.32isoquinoline alkaloid of opium. new text begin ; new text end 15.33(d) new text begin (4) new text end not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not 15.34more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients 15.35in recognized therapeutic amounts. new text begin ; new text end 16.1(e) new text begin (5) new text end not more than 1.80 grams of dihydrocodeine per 100 milliliters or not more 16.2than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in 16.3recognized therapeutic amounts. new text begin ; new text end 16.4(f) new text begin (6) new text end not more than 300 milligrams of ethylmorphine per 100 milliliters or not more 16.5than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in 16.6recognized therapeutic amounts. new text begin ; new text end 16.7(g) new text begin (7) new text end not more than 500 milligrams of opium per 100 milliliters or per 100 grams, 16.8or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic 16.9ingredients in recognized therapeutic amounts. new text begin ; new text end 16.10(h) new text begin (8) new text end not more than 50 milligrams of morphine per 100 milliliters or per 100 grams 16.11with one or more active, nonnarcotic ingredients in recognized therapeutic amounts. new text begin ; new text end 16.12(6) new text begin (f) new text end Anabolic steroids, which new text begin and human growth hormone. new text end 16.13 new text begin (1) Anabolic steroids new text end , for purposes of this subdivision, means any drug or 16.14hormonal substance, chemically and pharmacologically related to testosterone, other 16.15than estrogens, progestins, corticosteroids, and dehydroepiandrosterone, and includes: 16.16androstanediol; androstanedione; androstenediol; androstenedione; bolasterone; 16.17boldenone; calusterone; chlorotestosterone; chorionic gonadotropin; clostebol; 16.18dehydrochloromethyltestosterone; (triangle)1-dihydrotestosterone; 4-dihydrotestosterone; 16.19drostanolone; ethylestrenol; fluoxymesterone; formebolone; furazabol; human 16.20growth hormones; 13b-ethyl-17a-hydroxygon-4-en-3-one; 4-hydroxytestosterone; 16.214-hydroxy-19-nortestosterone; mestanolone; mesterolone; methandienone; 16.22methandranone; methandriol; methandrostenolone; methenolone; 17a-methyl-3b, 16.2317b-dihydroxy-5a-androstane; 17a-methyl-3a, 17b-dihydroxy-5a-androstane; 16.2417a-methyl-3b, 17b-dihydroxyandrost-4-ene; 17a-methyl-4-hydroxynandrolone; 16.25methyldienolone; methyltrienolone; methyltestosterone; mibolerone; 16.2617a-methyl-(triangle)1-dihydrotestosterone; nandrolone; nandrolone phenpropionate; 16.27norandrostenediol; norandrostenedione; norbolethone; norclostebol; norethandrolone; 16.28normethandrolone; oxandrolone; oxymesterone; oxymetholone; stanolone; stanozolol; 16.29stenbolone; testolactone; testosterone; testosterone propionate; tetrahydrogestrinone; 16.30trenbolone; and any salt, ester, or ether of a drug or substance described in this paragraph. 16.31 new text begin (i) 3[beta],17[beta]-dihydroxy-5[alpha]-androstane; new text end 16.32 new text begin (ii) 3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; new text end 16.33 new text begin (iii) androstanedione (5[alpha]-androstan-3,17-dione); new text end 16.34 new text begin (iv) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-l-ene; new text end 16.35 new text begin (v) 3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene); new text end 16.36 new text begin (vi) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene); new text end 17.1 new text begin (vii) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene); new text end 17.2 new text begin (viii) 1-androstenedione (5[alpha]-androst-1-en-3,17-dione); new text end 17.3 new text begin (ix) 4-androstenedione (androst-4-en-3,17-dione); new text end 17.4 new text begin (x) 5-androstenedione (androst-5-en-3,17-dione); new text end 17.5 new text begin (xi) bolasterone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); new text end 17.6 new text begin (xii) boldenone (17[beta]-hydroxyandrost-1,4-diene-3-one); new text end 17.7 new text begin (xiii) boldione (androsta-1,4-diene-3,17-dione); new text end 17.8 new text begin (xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one); new text end 17.9 new text begin (xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one); new text end 17.10 new text begin (xvi) dehydrochloromethyltestosterone new text end 17.11 new text begin (4-chloro-17[beta]-hydroxy-17[alpha]-methylandrost-1,4-dien-3-one); new text end 17.12 new text begin (xvii) desoxymethyltestosterone new text end 17.13 new text begin (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol); new text end 17.14 new text begin (xviii) [delta]1-dihydrotestosterone- new text end 17.15 new text begin (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); new text end 17.16 new text begin (xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one); new text end 17.17 new text begin (xx) drostanolone (17[beta]hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one); new text end 17.18 new text begin (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene); new text end 17.19 new text begin (xxii) fluoxymesterone new text end 17.20 new text begin (9-fluoro-17[alpha]-methyl-11[beta],17[beta]-dihydroxyandrost-4-en-3-one); new text end 17.21 new text begin (xxiii) formebolone new text end 17.22 new text begin (2-formyl-17[alpha]-methyl-11[alpha],17[beta]-dihydroxyandrost-1,4-dien-3-one); new text end 17.23 new text begin (xxiv) furazabol new text end 17.24 new text begin (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]-furazan)13[beta]-ethyl-17[beta] new text end 17.25 new text begin -hydroxygon-4-en-3-one; new text end 17.26 new text begin (xxv) 4-hydroxytestosterone (4,17[beta]-dihydroxyandrost-4-en-3-one); new text end 17.27 new text begin (xxvi) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3-one); new text end 17.28 new text begin (xxvii) mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); new text end 17.29 new text begin (xxviii) mesterolone (1[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androstan-3-one); new text end 17.30 new text begin (xxix) methandienone (17[alpha]-methyl-17[beta]-hydroxyandrost-1,4-dien-3-one); new text end 17.31 new text begin (xxx) methandriol (17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-5-ene); new text end 17.32 new text begin (xxxi) methenolone (1-methyl-17[beta]-hydroxy-5[alpha]-androst-1-en-3-one); new text end 17.33 new text begin (xxxii) 17[alpha]-methyl-3[beta],17[beta]-dihydroxy-5[alpha]-androstane; new text end 17.34 new text begin (xxxiii) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5[alpha]-androstane; new text end 17.35 new text begin (xxxiv) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene; new text end 18.1 new text begin (xxxv) 17[alpha]-methyl-4-hydroxynandrolone new text end 18.2 new text begin (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one); new text end 18.3 new text begin (xxxvi) methyldienolone new text end 18.4 new text begin (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one); new text end 18.5 new text begin (xxxvii) methyltrienolone new text end 18.6 new text begin (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one); new text end 18.7 new text begin (xxxviii) methyltestosterone new text end 18.8 new text begin (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one); new text end 18.9 new text begin (xxxix) mibolerone (7[alpha],17[alpha]-dimethyl-17[beta]-hydroxyestr-4-en-3-one); new text end 18.10 new text begin (xl) 17[alpha]-methyl-[delta]1-dihydrotestosterone new text end 18.11 new text begin (17[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one); new text end 18.12 new text begin (xli) nandrolone (17[beta]-hydroxyestr-4-en-3-one); new text end 18.13 new text begin (xlii) 19-nor-4-androstenediol (3[beta],17[beta]-dihydroxyestr-4-ene; new text end 18.14 new text begin (xliii) 3[alpha],17[beta]-dihydroxyestr-4-ene); 19-nor-5-androstenediol new text end 18.15 new text begin (3[beta],17[beta]-dihydroxyestr-5-ene; new text end 18.16 new text begin (xliv) 3[alpha],17[beta]-dihydroxyestr-5-ene); new text end 18.17 new text begin (xlv) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione); new text end 18.18 new text begin (xlvi) 19-nor-5-androstenedione (estr-5-en-3,17-dione); new text end 18.19 new text begin (xlvii) norbolethone (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4-en-3-one); new text end 18.20 new text begin (xlviii) norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one); new text end 18.21 new text begin (xlix) norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3-one); new text end 18.22 new text begin (l) normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one); new text end 18.23 new text begin (li) oxandrolone new text end 18.24 new text begin (17[alpha]-methyl-17[beta]-hydroxy-2-oxa-5[alpha]-androstan-3-one); new text end 18.25 new text begin (lii) oxymesterone (17[alpha]-methyl-4,17[beta]-dihydroxyandrost-4-en-3-one); new text end 18.26 new text begin (liii) oxymetholone new text end 18.27 new text begin (17[alpha]-methyl-2-hydroxymethylene-17[beta]-hydroxy-5[alpha]-androstan-3-one); new text end 18.28 new text begin (liv) stanozolol new text end 18.29 new text begin (17[alpha]-methyl-17[beta]-hydroxy-5[alpha]-androst-2-eno[3,2-c]-pyrazole); new text end 18.30 new text begin (lv) stenbolone (17[beta]-hydroxy-2-methyl-5[alpha]-androst-1-en-3-one); new text end 18.31 new text begin (lvi) testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid new text end 18.32 new text begin lactone); new text end 18.33 new text begin (lvii) testosterone (17[beta]-hydroxyandrost-4-en-3-one); new text end 18.34 new text begin (lviii) tetrahydrogestrinone new text end 18.35 new text begin (13[beta],17[alpha]-diethyl-17[beta]-hydroxygon-4,9,11-trien-3-one); new text end 18.36 new text begin (lix) trenbolone (17[beta]-hydroxyestr-4,9,11-trien-3-one); new text end 19.1 new text begin (lx) any salt, ester, or ether of a drug or substance described in this paragraph. new text end 19.2Anabolic steroids are not included if they are: (i) new text begin (A) new text end expressly intended for administration 19.3through implants to cattle or other nonhuman species; and (ii) new text begin (B) new text end approved by the United 19.4States Food and Drug Administration for that use. new text begin ; new text end 19.5 new text begin (2) Human growth hormones. new text end 19.6 new text begin (g) Hallucinogenic substances. Dronabinol (synthetic) in sesame oil and new text end 19.7 new text begin encapsulated in a soft gelatin capsule in a United States Food and Drug Administration new text end 19.8 new text begin approved product. new text end 19.9 new text begin (h) Any material, compound, mixture, or preparation containing the following new text end 19.10 new text begin narcotic drug or its salt: buprenorphine. new text end 19.11    Subd. 5. Schedule IV. The following items are listed in Schedule IV: Barbital; 19.12Butorphanol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clonazepam; 19.13Clorazepate; Diazepam; Diethylpropion; Ethchlorvynol; Ethinamate; Fenfluramine; 19.14Flurazepam; Mebutamate; Methohexital; Meprobamate except when in combination with 19.15the following drugs in the following or lower concentrations: conjugated estrogens, 0.4 19.16mg; tridihexethyl chloride, 25mg; pentaerythritol tetranitrate, 20 mg; Methylphenobarbital; 19.17Oxazepam; Paraldehyde; Pemoline; Petrichloral; Phenobarbital; and Phentermine new text begin (a) new text end 19.18 new text begin Schedule IV consists of the substances listed in this subdivision new text end . 19.19 new text begin (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, new text end 19.20 new text begin any material, compound, mixture, or preparation containing any of the following narcotic new text end 19.21 new text begin drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities new text end 19.22 new text begin as follows: new text end 19.23 new text begin (1) not more than one milligram of difenoxin and not less than 25 micrograms of new text end 19.24 new text begin atropine sulfate per dosage unit; new text end 19.25 new text begin (2) dextropropoxyphene (Darvon and Darvocet). new text end 19.26 new text begin (c) Depressants. Unless specifically excepted or unless listed in another schedule, new text end 19.27 new text begin any material, compound, mixture, or preparation containing any quantity of the following new text end 19.28 new text begin substances, including its salts, isomers, and salts of isomers whenever the existence of the new text end 19.29 new text begin salts, isomers, and salts of isomers is possible: new text end 19.30 new text begin (1) alprazolam; new text end 19.31 new text begin (2) barbital; new text end 19.32 new text begin (3) bromazepam; new text end 19.33 new text begin (4) camazepam; new text end 19.34 new text begin (5) carisoprodol; new text end 19.35 new text begin (6) chloral betaine; new text end 19.36 new text begin (7) chloral hydrate; new text end 20.1 new text begin (8) chlordiazepoxide; new text end 20.2 new text begin (9) clobazam; new text end 20.3 new text begin (10) clonazepam; new text end 20.4 new text begin (11) clorazepate; new text end 20.5 new text begin (12) clotiazepam; new text end 20.6 new text begin (13) cloxazolam; new text end 20.7 new text begin (14) delorazepam; new text end 20.8 new text begin (15) diazepam; new text end 20.9 new text begin (16) dichloralphenazone; new text end 20.10 new text begin (17) estazolam; new text end 20.11 new text begin (18) ethchlorvynol; new text end 20.12 new text begin (19) ethinamate; new text end 20.13 new text begin (20) ethyl loflazepate; new text end 20.14 new text begin (21) fludiazepam; new text end 20.15 new text begin (22) flurazepam; new text end 20.16 new text begin (23) halazepam; new text end 20.17 new text begin (24) haloxazolam; new text end 20.18 new text begin (25) ketazolam; new text end 20.19 new text begin (26) loprazolam; new text end 20.20 new text begin (27) lorazepam; new text end 20.21 new text begin (28) lormetazepam mebutamate; new text end 20.22 new text begin (29) medazepam; new text end 20.23 new text begin (30) meprobamate; new text end 20.24 new text begin (31) methohexital; new text end 20.25 new text begin (32) methylphenobarbital; new text end 20.26 new text begin (33) midazolam; new text end 20.27 new text begin (34) nimetazepam; new text end 20.28 new text begin (35) nitrazepamnordiazepam; new text end 20.29 new text begin (36) oxazepam; new text end 20.30 new text begin (37) oxazolam; new text end 20.31 new text begin (38) paraldehydepetrichloral; new text end 20.32 new text begin (39) phenobarbital; new text end 20.33 new text begin (40) pinazepam; new text end 20.34 new text begin (41) prazepam; new text end 20.35 new text begin (42) quazepam; new text end 20.36 new text begin (43) temazepam; new text end 21.1 new text begin (44) tetrazepam; new text end 21.2 new text begin (45) triazolam; new text end 21.3 new text begin (46) zaleplon; new text end 21.4 new text begin (47) zolpidem; new text end 21.5 new text begin (48) zopiclone. new text end 21.6 new text begin (d) Any material, compound, mixture, or preparation which contains any quantity of new text end 21.7 new text begin the following substance including its salts, isomers, and salts of such isomers, whenever new text end 21.8 new text begin the existence of such salts, isomers, and salts of isomers is possible: fenfluramine. new text end 21.9 new text begin (e) Stimulants. Unless specifically excepted or unless listed in another schedule, new text end 21.10 new text begin any material, compound, mixture, or preparation which contains any quantity of the new text end 21.11 new text begin following substances having a stimulant effect on the central nervous system, including its new text end 21.12 new text begin salts, isomers, and salts of isomers: new text end 21.13 new text begin (1) cathine (norpseudoephedrine); new text end 21.14 new text begin (2) diethylpropion; new text end 21.15 new text begin (3) fencamfamine; new text end 21.16 new text begin (4) fenproporex; new text end 21.17 new text begin (5) mazindol; new text end 21.18 new text begin (6) mefenorex; new text end 21.19 new text begin (7) modafinil; new text end 21.20 new text begin (8) pemoline (including organometallic complexes and chelates thereof); new text end 21.21 new text begin (9) phentermine; new text end 21.22 new text begin (10) pipradol; new text end 21.23 new text begin (11) sibutramine; new text end 21.24 new text begin (12) SPA (1-dimethylamino-1,2-diphenylethane). new text end 21.25    Subd. 6. Schedule V; restrictions on methamphetamine precursor drugs. (a) As 21.26used in this subdivision, the following terms have the meanings given: 21.27(1) "methamphetamine precursor drug" means any compound, mixture, or 21.28preparation intended for human consumption containing ephedrine or pseudoephedrine as 21.29its sole active ingredient or as one of its active ingredients; and 21.30(2) "over-the-counter sale" means a retail sale of a drug or product but does not 21.31include the sale of a drug or product pursuant to the terms of a valid prescription. 21.32(b) The following items are listed in Schedule V: 21.33(1) any compound, mixture, or preparation containing any of the following limited 21.34quantities of narcotic drugs, which shall include one or more nonnarcotic active medicinal 21.35ingredients in sufficient proportion to confer upon the compound, mixture or preparation 21.36valuable medicinal qualities other than those possessed by the narcotic drug alone: 22.1(i) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 22.2grams; 22.3(ii) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 22.4grams; 22.5(iii) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms 22.6of atropine sulfate per dosage unit; or 22.7(iv) not more than 15 milligrams of anhydrous morphine per 100 milliliters or per 22.8100 grams; and new text begin 100 milligrams of opium per 100 milliliters or per 100 grams; or new text end 22.9 new text begin (v) not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of new text end 22.10 new text begin atropine sulfate per dosage unit. new text end 22.11 new text begin (2) Stimulants. Unless specifically exempted or excluded or unless listed in another new text end 22.12 new text begin schedule, any material, compound, mixture, or preparation that contains any quantity of new text end 22.13 new text begin the following substance having a stimulant effect on the central nervous system, including new text end 22.14 new text begin its salts, isomers, and salts of isomers: pyrovalerone. new text end 22.15 new text begin (3) Depressants. Unless specifically exempted or excluded or unless listed in another new text end 22.16 new text begin schedule, any material, compound, mixture, or preparation that contains any quantity new text end 22.17 new text begin of the following substance having a depressant effect on the central nervous system, new text end 22.18 new text begin including its salts, isomers, and salts of isomers: new text end 22.19 new text begin (i) pregabalin; new text end 22.20 new text begin (ii) lacosamide. new text end 22.21(2) new text begin (4) new text end Any compound, mixture, or preparation containing ephedrine or 22.22pseudoephedrine as its sole active ingredient or as one of its active ingredients. 22.23(c) No person may sell in a single over-the-counter sale more than two packages 22.24of a methamphetamine precursor drug or a combination of methamphetamine precursor 22.25drugs or any combination of packages exceeding a total weight of six grams, calculated as 22.26the base. 22.27(d) Over-the-counter sales of methamphetamine precursor drugs are limited to: 22.28(1) packages containing not more than a total of three grams of one or 22.29more methamphetamine precursor drugs, calculated in terms of ephedrine base or 22.30pseudoephedrine base; or 22.31(2) for nonliquid products, sales in blister packs, where each blister contains not 22.32more than two dosage units, or, if the use of blister packs is not technically feasible, sales 22.33in unit dose packets or pouches. 22.34(e) A business establishment that offers for sale methamphetamine precursor drugs 22.35in an over-the-counter sale shall ensure that all packages of the drugs are displayed 22.36behind a checkout counter where the public is not permitted and are offered for sale only 23.1by a licensed pharmacist, a registered pharmacy technician, or a pharmacy clerk. The 23.2establishment shall ensure that the person making the sale requires the buyer: 23.3(1) to provide photographic identification showing the buyer's date of birth; and 23.4(2) to sign a written or electronic document detailing the date of the sale, the name 23.5of the buyer, and the amount of the drug sold. 23.6A document described under clause (2) must be retained by the establishment for 23.7at least three years and must at all reasonable times be open to the inspection of any 23.8law enforcement agency. 23.9Nothing in this paragraph requires the buyer to obtain a prescription for the drug's 23.10purchase. 23.11(f) No person may acquire through over-the-counter sales more than six grams of 23.12methamphetamine precursor drugs, calculated as the base, within a 30-day period. 23.13(g) No person may sell in an over-the-counter sale a methamphetamine precursor 23.14drug to a person under the age of 18 years. It is an affirmative defense to a charge under 23.15this paragraph if the defendant proves by a preponderance of the evidence that the 23.16defendant reasonably and in good faith relied on proof of age as described in section 23.17340A.503, subdivision 6 . 23.18(h) A person who knowingly violates paragraph (c), (d), (e), (f), or (g) is guilty of 23.19a misdemeanor and may be sentenced to imprisonment for not more than 90 days, or to 23.20payment of a fine of not more than $1,000, or both. 23.21(i) An owner, operator, supervisor, or manager of a business establishment that 23.22offers for sale methamphetamine precursor drugs whose employee or agent is convicted of 23.23or charged with violating paragraph (c), (d), (e), (f), or (g) is not subject to the criminal 23.24penalties for violating any of those paragraphs if the person: 23.25(1) did not have prior knowledge of, participate in, or direct the employee or agent to 23.26commit the violation; and 23.27(2) documents that an employee training program was in place to provide the 23.28employee or agent with information on the state and federal laws and regulations regarding 23.29methamphetamine precursor drugs. 23.30(j) Any person employed by a business establishment that offers for sale 23.31methamphetamine precursor drugs who sells such a drug to any person in a suspicious 23.32transaction shall report the transaction to the owner, supervisor, or manager of the 23.33establishment. The owner, supervisor, or manager may report the transaction to local law 23.34enforcement. A person who reports information under this subdivision in good faith is 23.35immune from civil liability relating to the report. 23.36(k) Paragraphs (b) to (j) do not apply to: 24.1(1) pediatric products labeled pursuant to federal regulation primarily intended for 24.2administration to children under 12 years of age according to label instructions; 24.3(2) methamphetamine precursor drugs that are certified by the Board of Pharmacy as 24.4being manufactured in a manner that prevents the drug from being used to manufacture 24.5methamphetamine; 24.6(3) methamphetamine precursor drugs in gel capsule or liquid form; or 24.7(4) compounds, mixtures, or preparations in powder form where pseudoephedrine 24.8constitutes less than one percent of its total weight and is not its sole active ingredient. 24.9(l) The Board of Pharmacy, in consultation with the Department of Public Safety, 24.10shall certify methamphetamine precursor drugs that meet the requirements of paragraph 24.11(k), clause (2), and publish an annual listing of these drugs. 24.12(m) Wholesale drug distributors licensed and regulated by the Board of Pharmacy 24.13pursuant to sections 151.42 to 151.51 and registered with and regulated by the United 24.14States Drug Enforcement Administration are exempt from the methamphetamine precursor 24.15drug storage requirements of this section. 24.16(n) This section preempts all local ordinances or regulations governing the sale 24.17by a business establishment of over-the-counter products containing ephedrine or 24.18pseudoephedrine. All ordinances enacted prior to the effective date of this act are void. 24.19    Subd. 7. Board of Pharmacy; regulation of substances. The Board of Pharmacy 24.20is authorized to regulate and define additional substances which contain quantities of a 24.21substance possessing abuse potential in accordance with the following criteria: 24.22(1) The Board of Pharmacy shall place a substance in Schedule I if it finds that the 24.23substance has: A high potential for abuse, no currently accepted medical use in the United 24.24States, and a lack of accepted safety for use under medical supervision. 24.25(2) The Board of Pharmacy shall place a substance in Schedule II if it finds that the 24.26substance has: A high potential for abuse, currently accepted medical use in the United 24.27States, or currently accepted medical use with severe restrictions, and that abuse may lead 24.28to severe psychological or physical dependence. 24.29(3) The Board of Pharmacy shall place a substance in Schedule III if it finds that the 24.30substance has: A potential for abuse less than the substances listed in Schedules I and II, 24.31currently accepted medical use in treatment in the United States, and that abuse may lead 24.32to moderate or low physical dependence or high psychological dependence. 24.33(4) The Board of Pharmacy shall place a substance in Schedule IV if it finds that 24.34the substance has: A low potential for abuse relative to the substances in Schedule III, 24.35currently accepted medical use in treatment in the United States, and that abuse may lead 25.1to limited physical dependence or psychological dependence relative to the substances in 25.2Schedule III. 25.3(5) The Board of Pharmacy shall place a substance in Schedule V if it finds that the 25.4substance has: A low potential for abuse relative to the substances listed in Schedule IV, 25.5currently accepted medical use in treatment in the United States, and limited physical 25.6dependence and/or psychological dependence liability relative to the substances listed 25.7in Schedule IV. 25.8    Subd. 8. Add, delete, or reschedule substances. The state Board of Pharmacy may, 25.9by rule, add substances to or delete or reschedule substances listed in this section. The 25.10Board of Pharmacy may not delete or reschedule a drug that is in Schedule I, except as 25.11provided in subdivision 12. 25.12In making a determination regarding a substance, the Board of Pharmacy shall 25.13consider the following: The actual or relative potential for abuse, the scientific evidence 25.14of its pharmacological effect, if known, the state of current scientific knowledge 25.15regarding the substance, the history and current pattern of abuse, the scope, duration, 25.16and significance of abuse, the risk to public health, the potential of the substance to 25.17produce psychic or physiological dependence liability, and whether the substance is an 25.18immediate precursor of a substance already controlled under this section. The state Board 25.19of Pharmacy may include any nonnarcotic drug authorized by federal law for medicinal 25.20use in a schedule only if such drug must, under either federal or state law or rule, be 25.21sold only on prescription. 25.22    Subd. 8a. Methamphetamine precursors. The State Board of Pharmacy may, 25.23by order, require that nonprescription ephedrine or pseudophedrine products sold in 25.24gel capsule or liquid form be subject to the sale restrictions established in subdivision 25.256 for methamphetamine precursor drugs, if the board concludes that ephedrine or 25.26pseudophedrine products in gel capsule or liquid form can be used to manufacture 25.27methamphetamine. In assessing the need for an order under this subdivision, the board 25.28shall consult at least annually with the advisory council on controlled substances, the 25.29commissioner of public safety, and the commissioner of health. 25.30     new text begin Subd. 8b. new text end new text begin Board of Pharmacy; expedited scheduling of additional substances. new text end 25.31 new text begin (a) The state Board of Pharmacy may, by rule, add a substance to Schedule I provided that new text end 25.32 new text begin it finds that the substance has a high potential for abuse, has no currently accepted medical new text end 25.33 new text begin use in the United States, has a lack of accepted safety for use under medical supervision, new text end 25.34 new text begin has known adverse health effects, and is currently available for use within the state. For new text end 25.35 new text begin the purposes of this subdivision only, the board may use the expedited rulemaking process new text end 25.36 new text begin under section 14.389. The scheduling of a substance under this subdivision expires the new text end 26.1 new text begin day after the adjournment of the legislative session immediately following the substance's new text end 26.2 new text begin scheduling unless the legislature by law ratifies the action. new text end 26.3 new text begin (b) If the board schedules a substance under this subdivision, the board shall notify new text end 26.4 new text begin in a timely manner the chairs and ranking minority members of the senate and house of new text end 26.5 new text begin representatives committees having jurisdiction over criminal justice and health policy new text end 26.6 new text begin and finance of the action and the reasons for it. The notice must include a copy of the new text end 26.7 new text begin administrative law judge's decision on the matter. new text end 26.8 new text begin (c) This subdivision expires August 1, 2014. new text end 26.9    Subd. 9. Except substances by rule. The state Board of Pharmacy may by rule 26.10except any compound, mixture, or preparation containing any stimulant or depressant 26.11substance listed in subdivision 4, clauses (1) and (2) new text begin paragraphs (b) and (c), new text end or in 26.12subdivisions 5 and 6 from the application of all or any part of this chapter, if the 26.13compound, mixture, or preparation contains one or more active medicinal ingredients not 26.14having a stimulant or depressant effect on the central nervous system; provided, that 26.15such admixtures shall be included therein in such combinations, quantity, proportion, 26.16or concentration as to vitiate the potential for abuse of the substances which do have a 26.17stimulant or depressant effect on the central nervous system. 26.18    Subd. 10. Dextromethorphan. Dextromethorphan shall not be deemed to be 26.19included in any schedule by reason of the enactment of Laws 1971, chapter 937, unless 26.20controlled pursuant to the foregoing provisions of this section. 26.21    Subd. 12. Coordination of controlled substance regulation with federal law and 26.22state statute. If any substance is designated, rescheduled, or deleted as a controlled 26.23substance under federal law and notice thereof is given to the state Board of Pharmacy, the 26.24state Board of Pharmacy shall similarly control the substance under this chapter, after the 26.25expiration of 30 days from publication in the Federal Register of a final order designating 26.26a substance as a controlled substance or rescheduling or deleting a substance. Such order 26.27shall be filed with the secretary of state. If within that 30-day period, the state Board of 26.28Pharmacy objects to inclusion, rescheduling, or deletion, it shall publish the reasons for 26.29objection and afford all interested parties an opportunity to be heard. At the conclusion of 26.30the hearing, the state Board of Pharmacy shall publish its decision, which shall be subject 26.31to the provisions of chapter 14. 26.32In exercising the authority granted by this chapter, the state Board of Pharmacy shall 26.33be subject to the provisions of chapter 14. The state Board of Pharmacy shall provide 26.34copies of any proposed rule under this chapter to the advisory council on controlled 26.35substances at least 30 days prior to any hearing required by section 14.14, subdivision 1. 27.1The state Board of Pharmacy shall consider the recommendations of the advisory council 27.2on controlled substances, which may be made prior to or at the hearing. 27.3The state Board of Pharmacy shall annually submit a report to the legislature on or 27.4before December 1 that specifies what changes the board made to the controlled substance 27.5schedules maintained by the board in Minnesota Rules, parts 6800.4210 to 6800.4250, in 27.6the preceding 12 months. The report must include specific recommendations for amending 27.7the controlled substance schedules contained in subdivisions 2 to 6, so that they conform 27.8with the controlled substance schedules maintained by the board in Minnesota Rules, 27.9parts 6800.4210 to 6800.4250. 27.10    Subd. 13. Implementation study. Annually, the state Board of Pharmacy shall study 27.11the implementation of this chapter in relation to the problems of drug abuse in Minnesota. 27.12 new text begin EFFECTIVE DATE. new text end new text begin This section is effective August 1, 2012, and applies to crimes new text end 27.13 new text begin committed on or after that date. new text end 27.14    Sec. 2. Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6, is 27.15amended to read: 27.16    Subd. 6. Sale or possession of synthetic cannabinoids. (a) As used in this 27.17subdivision, "synthetic cannabinoid" includes any substance included in section 152.02, 27.18subdivision 2, new text begin paragraph (h), new text end clause (7) new text begin (3) new text end . 27.19(b) new text begin A person who unlawfully sells a synthetic cannabinoid for no remuneration is new text end 27.20 new text begin guilty of a gross misdemeanor. new text end 27.21 new text begin (c) new text end A person who unlawfully sells any amount of a synthetic cannabinoid is guilty of 27.22a gross misdemeanor new text begin felony and if convicted may be sentenced to imprisonment for not new text end 27.23 new text begin more than five years or to payment of a fine of not more than $10,000, or both new text end . 27.24(c) new text begin (d) new text end A person who unlawfully possesses any amount of a synthetic cannabinoid is 27.25guilty of a misdemeanor. 27.26(d) new text begin (e) new text end Notwithstanding any contrary provision in sections 152.021 to 152.025, this 27.27subdivision describes the exclusive penalties for the sale and possession of synthetic 27.28cannabinoid. 27.29 new text begin EFFECTIVE DATE. new text end new text begin This section is effective August 1, 2012, and applies to crimes new text end 27.30 new text begin committed on or after that date. new text end 27.31    Sec. 3. Minnesota Statutes 2010, section 152.18, subdivision 1, is amended to read: 27.32    Subdivision 1. Deferring prosecution for certain first time drug offenders. If 27.33any person who has not previously participated in or completed a diversion program 28.1authorized under section 401.065 or who has not previously been placed on probation 28.2without a judgment of guilty and thereafter been discharged from probation under 28.3this section is found guilty of a violation of section 152.024, subdivision 2, 152.025, 28.4subdivision 2 , or 152.027, subdivision 2, 3, or 4, new text begin or 6, paragraph (d), new text end for possession of a 28.5controlled substance, after trial or upon a plea of guilty, and the court determines that the 28.6violation does not qualify as a subsequent controlled substance conviction under section 28.7152.01, subdivision 16a , the court may, without entering a judgment of guilty and with the 28.8consent of the person, defer further proceedings and place the person on probation upon 28.9such reasonable conditions as it may require and for a period, not to exceed the maximum 28.10sentence provided for the violation. The court may give the person the opportunity to 28.11attend and participate in an appropriate program of education regarding the nature and 28.12effects of alcohol and drug abuse as a stipulation of probation. Upon violation of a 28.13condition of the probation, the court may enter an adjudication of guilt and proceed as 28.14otherwise provided. The court may, in its discretion, dismiss the proceedings against the 28.15person and discharge the person from probation before the expiration of the maximum 28.16period prescribed for the person's probation. If during the period of probation the person 28.17does not violate any of the conditions of the probation, then upon expiration of the period 28.18the court shall discharge the person and dismiss the proceedings against that person. 28.19Discharge and dismissal under this subdivision shall be without court adjudication of guilt, 28.20but a not public record of it shall be retained by the Bureau of Criminal Apprehension 28.21for the purpose of use by the courts in determining the merits of subsequent proceedings 28.22against the person. The not public record may also be opened only upon court order for 28.23purposes of a criminal investigation, prosecution, or sentencing. Upon request by law 28.24enforcement, prosecution, or corrections authorities, the bureau shall notify the requesting 28.25party of the existence of the not public record and the right to seek a court order to open it 28.26pursuant to this section. The court shall forward a record of any discharge and dismissal 28.27under this subdivision to the bureau which shall make and maintain the not public record 28.28of it as provided under this subdivision. The discharge or dismissal shall not be deemed a 28.29conviction for purposes of disqualifications or disabilities imposed by law upon conviction 28.30of a crime or for any other purpose. 28.31For purposes of this subdivision, "not public" has the meaning given in section 28.3213.02, subdivision 8a . 28.33 new text begin EFFECTIVE DATE. new text end new text begin This section is effective August 1, 2012, and applies to crimes new text end 28.34 new text begin committed on or after that date. new text end " 28.35Delete the title and insert: 28.36"A bill for an act 29.1relating to public safety; aligning state-controlled substance schedules with 29.2federal controlled substance schedules; modifying the authority of the Board of 29.3Pharmacy to regulate controlled substances; providing for penalties;amending 29.4Minnesota Statutes 2010, sections 152.02, as amended; 152.18, subdivision 1; 29.5Minnesota Statutes 2011 Supplement, section 152.027, subdivision 6." 30.1 We request the adoption of this report and repassage of the bill. 30.2 House Conferees: 30.3 ..... ..... 30.4 Bob Barrett John Kriesel 30.5 ..... 30.6 Kerry Gauthier 30.7 Senate Conferees: 30.8 ..... ..... 30.9 Scott J. Newman Bill G. Ingebrigtsen 30.10 ..... 30.11 Roger J. Reinert